EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates

Andrew W Hahn iD, Ganiraju C Manyam, Brian F Chapin, Miao Zhang, Yao Yu, Curtis A Pettaway, Lisly Chery, Louis L Pisters, John F Ward iD, Justin R Gregg iD, John Papadopoulos, Ashish M Kamat und 9 weitere

BJU International · 2024

DOI: 10.1111/bju.16414 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift BJU International, 2024. Verfasst von Andrew W Hahn und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Thiohydantoins, Prostatic Neoplasms, Prostatectomy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: U.S. Department of Defense, Prostate Cancer Foundation, Janssen Scientific Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine whether 6 months of preoperative apalutamide for intermediate‐risk prostate cancer (IRPCa) reduces the aggregate postoperative radiotherapy risk and to evaluate associations of molecular perturbations with clinical outcomes in this study cohort. Patients and Methods Between May 2018 and February 2020, eligible patients with IRPCa (Gleason 3 + 4 or 4 + 3 and clinical T2b‐c or prostate‐specific antigen level of 10–20 ng/mL) were treated with apalutamide 240 mg/day for 6 months followed by radical prostatectomy (RP) in this single‐arm, phase II trial. The primary endpoint was presence of any adverse pathological feature at risk of pelvic radiation (pathological T stage after neoadjuvant therapy [yp]T3 or ypN1 or positive surgical margins). Translational studies, including germline and somatic DNA alterations and RNA and protein expression, were performed on post‐apalutamide RP specimens, and assessed for associations with clinical outcomes.

Results

A total of 40 patients underwent a RP, and only one patient discontinued apalutamide prior to 6 months. In all, 40% had adverse pathological features at time of RP, and the 3‐year biochemical recurrence (BCR) rate was 15%, with 27.5% being not evaluable. Genomic alterations frequently seen in metastatic PCas, such as androgen receptor ( AR ), tumour protein p53 ( TP53 ), phosphatase and tensin homologue ( PTEN ), or BReast CAncer associated gene ( BRCA1/2 ) were underrepresented in this localised cohort. Adverse pathological features and BCR at 3‐years were associated with increased expression of select cell cycle (e.g., E2F targets: adjusted P value [ P adj ] < 0.001, normalised enrichment score [NES] 2.47) and oxidative phosphorylation ( P adj < 0.001, NES 1.62) pathways.

Conclusions

Preoperative apalutamide did not reduce the aggregate postoperative radiation risk to the pre‐specified threshold in unselected men with IRPCa. However, transcriptomic analysis identified key dysregulated pathways in tumours associated with adverse pathological outcomes and BCR, which warrant future study. Further investigation of preoperative therapy is underway for men with high‐risk PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiohydantoinsProstatic NeoplasmsProstatectomyHumansMaleMiddle AgedAged

Stichwörter der Autor:innen

E2Fapalutamidecell cycleintermediate riskneoadjuvantpreoperative

Substanzen

apalutamideThiohydantoins

Autor:innen und Institutionen

  • Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Basic Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Pathology and Laboratory Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Andrew W Hahn, John F Ward, Justin R Gregg

Förderung

  • U.S. Department of Defense
  • Prostate Cancer Foundation
  • Janssen Scientific Affairs
  • NCI NIH HHS

Zitieren

APA

Hahn, A. W., Manyam, G. C., Chapin, B. F., Zhang, M., Yu, Y., Pettaway, C. A., Chery, L., Pisters, L. L., Ward, J. F., Gregg, J. R., Papadopoulos, J., Kamat, A. M., Lozano, M., Hoang, A., Broom, B., Wang, X., Huff, C. D., Logothetis, C. J., Troncoso, P., …, & Davis, J. W. (2024). A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates. BJU International. https://doi.org/10.1111/bju.16414

Vancouver

Hahn AW, Manyam GC, Chapin BF, Zhang M, Yu Y, Pettaway CA, et al. A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates. BJU International. 2024. doi:10.1111/bju.16414

BibTeX
@article{Hahn2024,
  author = {Hahn, Andrew W and Manyam, Ganiraju C and Chapin, Brian F and Zhang, Miao and Yu, Yao and Pettaway, Curtis A and Chery, Lisly and Pisters, Louis L and Ward, John F and Gregg, Justin R and Papadopoulos, John and Kamat, Ashish M and Lozano, Marisa and Hoang, Anh and Broom, Bradley and Wang, Xuemei and Huff, Chad D and Logothetis, Christopher J and Troncoso, Patricia and Pilié, Patrick G and Davis, John W},
  title = {A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16414}
}
Kostenlos starten →